Monte Rosa Therapeutics (GLUE) Equity Ratio (2023 - 2025)
Monte Rosa Therapeutics' Equity Ratio history spans 3 years, with the latest figure at 0.52 for Q4 2025.
- For Q4 2025, Equity Ratio rose 2.23% year-over-year to 0.52; the TTM value through Dec 2025 reached 0.52, up 2.23%, while the annual FY2025 figure was 0.52, 2.23% up from the prior year.
- Equity Ratio reached 0.52 in Q4 2025 per GLUE's latest filing, down from 0.53 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.79 in Q1 2023 to a low of 0.51 in Q4 2024.
- Average Equity Ratio over 3 years is 0.65, with a median of 0.65 recorded in 2024.
- Peak YoY movement for Equity Ratio: decreased 27.5% in 2024, then increased 22.39% in 2025.
- A 3-year view of Equity Ratio shows it stood at 0.59 in 2023, then fell by 13.89% to 0.51 in 2024, then increased by 2.23% to 0.52 in 2025.
- Per Business Quant, the three most recent readings for GLUE's Equity Ratio are 0.52 (Q4 2025), 0.53 (Q3 2025), and 0.75 (Q2 2025).